Prevention of Cognitive Impairment in the Midlife Women

키워드

참고문헌 (36)

1. Henderson VW., "Cognitive symptoms and disorders in the midlife woman", Female Patient, 36, pp.1~5 (2011)
2. Ward A., "Mild cognitive impairment : disparity of incidence and prevalence estimates", Alzheimers Dement, 8, pp.14~21 (2012)
3. Gauthier S., "Mild cognitive impairment", Lancet, 367, pp.1262~1270 (2006)
4. Haroutunian V., "Is there a neuropathology difference between mild cognitive impairment and dementia?", Dialogues Clin Neurosci, 11, pp.171~179 (2009)
5. DeLaGarza VW., "Pharmacologic treatment of Alzheimer's disease : an update", Am Fam Physician, 68, pp.1365~1372 (2003)
6. Zhou W., "Anti-neuroinflammatory agents for the treatment of Alzheimer's disease", Future Med Chem, 5, pp.1559~1571 (2013)
7. Giacobini E., "Invited review : Cholinesterase inhibitors for Alzheimer's disease therapy : from tacrine to future applications", Neurochem Int, 32, pp.413~419 (1998)
8. Sano M., "A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study", N Engl J Med, 336, pp.1216~1222 (1997)
9. Behl C., "Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach", Free Radic Biol Med, 33, pp.182~191 (2002)
10. Farina N., "Vitamin E for Alzheimer's dementia and mild cognitive impairment", Cochrane Database Syst Rev, 11, pp.CD002854~ (2012)
11. Stewart WF., "Risk of Alzheimer's disease and duration of NSAID use", Neurology, 48, pp.626~632 (1997)
12. in t' Veld BA., "Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease", N Engl J Med, 345, pp.1515~1521 (2001)
13. Scharf S., "A double-blind, placebo-controlled trial of diclofenac", misoprostol in Alzheimer's disease, 1999, pp.53, 197~201
14. Aisen PS., "A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study", Neurology, 54, pp.588~593 (2000)
15. Etminan M., "Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease : systematic review and meta-analysis of observational studies", BMJ, 327, pp.128~ (2003)
16. de Villiers TJ., "Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health", Climacteric, 16, pp.316~337 (2013)
17. Rapp SR., "Effect of estrogen plus progestin on global cognitive function in postmenopausal women : the Women's Health Initiative Memory Study : a randomized controlled trial", JAMA, 289, pp.2663~2672 (2003)
18. Espeland MA., "Conjugated equine estrogens and global cognitive function in postmenopausal women : Women's Health Initiative Memory Study", JAMA, 291, pp.2959~2968 (2004)
19. Espeland MA., "Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years", JAMA Intern Med, 173, pp.1429~1436 (2013)
20. Shao H., "Hormone therapy and Alzheimer disease dementia : new findings from the Cache County Study", Neurology, 79, pp.1846~1852 (2012)
21. Wharton W., "Rationale and design of the Kronos Early Estrogen Prevention Study(KEEPS)and the KEEPS Cognitive and Affective sub study(KEEPS Cog)", Brain Res, 1514, pp.12~17 (2013)
22. Wharton W., "The KEEPS-Cognitive and Affective Study : baseline associations between vascular risk factors and cognition", J Alzheimers Dis, 40, pp.331~341 (2014)
23. Petersen RC., "Vitamin E and donepezil for the treatment of mild cognitive impairment", N Engl J Med, 352, pp.2379~2388 (2005)
24. Blacker D., "Mild cognitive impairment-no benefit from vitamin E, little from donepezil", N Engl J Med, 352, pp.2439~2441 (2005)
25. Tayebati SK., "Choline-containing phospholipids : relevance to brain functional pathways", Clin Chem Lab Med, 51, pp.513~521 (2013)
26. Montgomery SA., "Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease", Int Clin Psychopharmacol, 18, pp.61~71 (2003)
27. De Jesus Moreno Moreno M., "Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate : a multicenter, double-blind, randomized, placebo-controlled trial", Clin Ther, 25, pp.178~193 (2003)
28. Di Perri R., "A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia", J Int Med Res, 19, pp.330~341 (1991)
29. Amenta F., "The cholinergic approach for the treatment of vascular dementia : evidence from pre-clinical and clinical studies", Clin Exp Hypertens, 24, pp.697~713 (2002)
30. Chertkow H., "Treating mild cognitive impairment", Can Rev Alzheimers Dis Other Dement, 8, pp.12~22 (2006)
31. Shifren JL., "The North American Menopause Society recommendations for clinical care of midlife women", Menopause, 21, pp.1038~1062 (2014)
32. Burke D., "Possibilities for the prevention and treatment of cognitive impairment and dementia", Br J Psychiatry, 190, pp.371~372 (2007)
33. Engelhart MJ., "Diet and risk of dementia : Does fat matter? : The Rotterdam Study", Neurology, 59, pp.1915~1921 (2002)
34. Yaffe K., "A prospective study of physical activity and cognitive decline in elderly women : women who walk", Arch Intern Med, 161, pp.1703~1708 (2001)
35. Andrade C., "The prevention and treatment of cognitive decline and dementia : An overview of recent research on experimental treatments", Indian J Psychiatry, 51, pp.12~25 (2009)
36. Gregory SM., "Physical activity, cognitive function, and brain health : what is the role of exercise training in the prevention of dementia?", Brain Sci, 2, pp.684~708 (2012)

관련 논문AI추천